1/15/2020 8:20:46 AM
Iovance Completes Patient Dosing In Registration-Enabling Cohort 4 Of C-144-01 Melanoma Study With Lifileucel
1/12/2020 8:07:27 PM
Iovance And Cellectis Enter Into Research Collaboration And Exclusive Worldwide License Deal
1/12/2020 8:05:00 PM
Iovance Biotherapeutics Obtains License To Develop And Commercialize Novel IL-2 Analog
10/2/2019 7:09:12 AM
Iovance Biotherapeutics Announces Four Abstracts Highlighting TIL Therapy To Be Presented At 2019 SITC Annual Meeting
7/18/2019 8:05:10 AM
Iovance Biotherapeutics Appoints Friedrich Graf Finckenstein As Chief Medical Officer
6/11/2019 7:11:20 AM
Iovance Biotherapeutics Appoints Athena Countouriotis To Board
4/3/2019 7:09:24 AM
Iovance Biotherapeutics To Present New Data From Ongoing Studies Of TIL Therapy At 2019 ASCO Meeting
2/26/2019 7:29:00 AM
Iovance Biotherapeutics: FDA Grants Fast Track Designation For LN-145 For Cervical Cancer
11/6/2018 8:13:19 AM
Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data From The Lifileucel Metastatic Melanoma Trial
10/18/2018 7:12:44 AM
Iovance Biotherapeutics And MaSTherCell Enter New Three-year Manufacturing Services Agreement
10/17/2018 7:05:15 AM
Iovance Biotherapeutics Closes Public Offering Of 25.30 Mln Shares Of Common Stock
10/12/2018 7:46:04 AM
Iovance Biotherapeutics Prices Public Offering Of 22 Mln Shares At $9.97 Per Share